Current and historical daily PE Ratio for Cambium Bio Ltd (
) from 2013 to Sep 22 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Cambium Bio stock (ASX:CMB) PE ratio as of Sep 22 2024 is 0.
More Details
Cambium Bio Ltd (ASX:CMB) PE Ratio (TTM) Chart
Cambium Bio Ltd (ASX:CMB) PE Ratio (TTM) Historical Data
View and export this data going back to 2013. Start your Free Trial
Total 1236
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Cambium Bio PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-09-22 | At Loss | 2024-07-22 | At Loss |
| 2024-09-20 | At Loss | 2024-07-19 | At Loss |
| 2024-09-19 | At Loss | 2024-07-18 | At Loss |
| 2024-09-18 | At Loss | 2024-07-17 | At Loss |
| 2024-09-17 | At Loss | 2024-07-16 | At Loss |
| 2024-09-16 | At Loss | 2024-07-15 | At Loss |
| 2024-09-13 | At Loss | 2024-07-12 | At Loss |
| 2024-09-12 | At Loss | 2024-07-11 | At Loss |
| 2024-09-11 | At Loss | 2024-07-10 | At Loss |
| 2024-09-10 | At Loss | 2024-07-09 | At Loss |
| 2024-09-09 | At Loss | 2024-07-08 | At Loss |
| 2024-09-06 | At Loss | 2024-07-05 | At Loss |
| 2024-09-05 | At Loss | 2024-07-04 | At Loss |
| 2024-09-04 | At Loss | 2024-07-03 | At Loss |
| 2024-09-03 | At Loss | 2024-07-02 | At Loss |
| 2024-09-02 | At Loss | 2024-07-01 | At Loss |
| 2024-08-30 | At Loss | 2024-06-28 | At Loss |
| 2024-08-29 | At Loss | 2024-06-27 | At Loss |
| 2024-08-28 | At Loss | 2024-06-26 | At Loss |
| 2024-08-27 | At Loss | 2024-06-25 | At Loss |
| 2024-08-26 | At Loss | 2024-06-24 | At Loss |
| 2024-08-23 | At Loss | 2024-06-21 | At Loss |
| 2024-08-22 | At Loss | 2024-06-20 | At Loss |
| 2024-08-21 | At Loss | 2024-06-19 | At Loss |
| 2024-08-20 | At Loss | 2024-06-18 | At Loss |
| 2024-08-19 | At Loss | 2024-06-17 | At Loss |
| 2024-08-16 | At Loss | 2024-06-14 | At Loss |
| 2024-08-15 | At Loss | 2024-06-13 | At Loss |
| 2024-08-14 | At Loss | 2024-06-12 | At Loss |
| 2024-08-13 | At Loss | 2024-06-11 | At Loss |
| 2024-08-12 | At Loss | 2024-06-10 | At Loss |
| 2024-08-09 | At Loss | 2024-06-07 | At Loss |
| 2024-08-08 | At Loss | 2024-06-06 | At Loss |
| 2024-08-07 | At Loss | 2024-06-05 | At Loss |
| 2024-08-06 | At Loss | 2024-06-04 | At Loss |
| 2024-08-05 | At Loss | 2024-06-03 | At Loss |
| 2024-08-02 | At Loss | 2024-05-31 | At Loss |
| 2024-08-01 | At Loss | 2024-05-30 | At Loss |
| 2024-07-31 | At Loss | 2024-05-29 | At Loss |
| 2024-07-30 | At Loss | 2024-05-28 | At Loss |
| 2024-07-29 | At Loss | 2024-05-27 | At Loss |
| 2024-07-26 | At Loss | 2024-05-24 | At Loss |
| 2024-07-25 | At Loss | 2024-05-23 | At Loss |
| 2024-07-24 | At Loss | 2024-05-22 | At Loss |
| 2024-07-23 | At Loss | 2024-05-21 | At Loss |
Cambium Bio Ltd (ASX:CMB) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Cambium Bio Ltd
ISIN : AU0000327769
Compare
Compare
Traded in other countries / regions
CMB.Australia IPO Date
2013-09-19Description
Cambium Bio Ltd, formerly Regeneus Ltd is a clinical-stage regenerative medicine company in Australia. The company develops a portfolio of cell-based therapies to address unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology, and dermatology diseases. The company uses stem cell and immuno-oncology technologies to develop cell-based therapies. The company's product pipeline consists of two platform technologies, Progenza and Sygenus, across three target therapeutic areas namely osteoarthritis, neuropathic pain, and skin wound healing.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers